Oxymetazoline
Oxymetazoline is one of the treatments to watch in the next couple of years. Oxymetazoline is at a high level similar to Mirvaso but is being progressed through clinical trials by Allergan under the name AGN 199201. This product was previously known as V-101 when it belonged to Vicept.
Recent Rosacea Blog Posts
In a document prepared for Allergan’s November 4, 2015 R&D Day presentation, Allergan is highlighting the development of its soon to be approved oxymetazoline 1% cream for rosacea. The slides relating to Oxymetazoline show the features of this product, along with other products in development, that Allergan wants to promote to investors. In the presentation […]
Two small updates on the progress of topical oxymetazoline (now known as Rhofade) towards being available as another treatment for the redness of rosacea. The update tells us firstly that Allergan’s Oxymetazoline based product is in indeed in the final stages of approval, having completed Phase 3 trials and been submitted to the FDA for […]
Allergan haven’t announced it yet, but it seems pretty clear that they are planning to use the brand name Azultro for their oxymetazoline based treatment for the erythema of rosacea. Azultro started life as V-101 when owned by Vicept Therapeutics. It was renamed as AGN-199201 after Allergan purchased Vicept. Actavis now owns Allergan. I had […]
Allergan have listed their Phase 3 trials details for AGN-199201, their Oxymetazoline based treatment, called AGN-199201, for the persistent red face associated with rosacea. Phase 3 trials like this one are interested in assessing the safety and efficacy of the active ingredient in a proposed treatment. Efficacy is proved by comparing the active treatment against […]
This paper from Hospital Pharmacy is giving a guarded approval for the use of Oxymetazoline topically for the redness of rosacea. Even though the FDA has not approved Oxymetazoline as a topical skin treatment, it is approved as a nasal decongestant. Doctors are able to prescribe drugs for off-label use, that is once a drug […]
